Amicus Therapeutics Reports Strong Q3 Growth and Raises Guidance
Daily NewsAmicus Therapeutics (NASDAQ: FOLD) reported a significant increase in revenue for the third quarter of 2024, reaching $142 million, which represents a 37% year-ov...
Read More